Clinical trial NCT03596450: Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial
Official title: Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Diabetes Mellitus, Type 2
Lead sponsor: Novo Nordisk A/S
Sponsor class: INDUSTRY
First posted: 2018-07-23
Enrollment: 1278
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main purpose of this study is to compare the effects of semaglutide (Ozempic®) with the effects of other treatments for type 2 diabetes in a normal practice setting. The participant will be assigned by chance (like flipping a coin) to one of the following treatment groups: Group 1: semaglutide (Ozempic®) (by injection into skin) Group 2: standard of care antidiabetic medication (oral or injectable). The participant has an equal chance of being in either of the treatment groups. Neither the participant nor the study doctor or study staff will be able to pick which group the participant is in, but the participant will know which study drug the participant has been assigned to. The study doctor will provide the participant with a prescription for the study diabetes medication based on the treatment group the participant is assigned. The participation will last about 2 years.


Eligibility criteria: Inclusion Criteria:-

* Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study.
* Male or female, age 18 years or older at the time of signing informed consent.
* Type 2 diabetes mellitus diagnosis.
* Treatment with either 1 or 2 oral antidiabetic medications.
* Current member of a commercial or Medicare health plan with pharmacy benefits.
* Recorded HbAlc value within the last 90 days prior to randomization.
* Further intensification with an additional antidiabetic oral or injectable medication is indicated to achieve glycemic target at the discretion of the study physician according to approved labelling.

Exclusion Criteria:

* Previous randomization in this study
* Treatment with more than 2 oral antidiabetic medications, oral semaglutide, or any injectable medication in a period of 30 days before the day of eligibility assessment. Temporary/emergency use of any type of insulin is allowed, as is prior insulin treatment for gestational diabetes.
* Contraindications to semaglutide according to the Food and Drug Administration approved label.
* Female who is pregnant, breastfeeding or intends to become pregnant
* Participation in another clinical trial.

Primary outcomes:
measure: Number of Participants With Glycosylated Haemoglobin (HbA1c) Less Than 7.0 Percentage (%) (53 Millimoles Per Mole [mmol/Mol]) at Year 1 (Yes/No)
timeFrame: At year 1
Secondary outcomes:
measure: Change in HbA1c (Percentage-point [%-Point]) From Baseline to Year 1
timeFrame: Baseline (less than or equal to 90 days prior to randomization at week 0), year 1
measure: Number of Participants With Glycosylated Haemoglobin (HbA1c) Less Than 7.0% (53 Millimoles Per Mole [mmol/Mol]) at Year 2 (Yes/No)
timeFrame: At year 2
measure: Change in HbA1c (Percentage-point [%-Point]) From Baseline to Year 2
timeFrame: Baseline (less than or equal to 90 days prior to randomization at week 0), year 2
measure: Number of Participants Who Attained Individualized HbA1c Target at Year 1 (Yes/No)
timeFrame: At year 1
measure: Number of Participants With HbA1c Less Than 7.0% (53 mmol/Mol) or At Least 1% Point Improvement in HbA1c Compared to Baseline at Year 1 (Yes/No)
timeFrame: At year 1
measure: Number of Participants With HbA1c Target Attainment Per Healthcare Effectiveness Data and Information Set (HEDIS) Criteria at Year 1 (Yes/No)
timeFrame: At year 1
measure: Change in Body Weight (in Pounds) From Baseline to Year 1
timeFrame: Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 1
measure: Percentage Change in Body Weight From Baseline to Year 1
timeFrame: Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 1
measure: Change in Systolic Blood Pressure (SBP) From Baseline to Year 1
timeFrame: Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 1
measure: Change in Diastolic Blood Pressure (DBP) From Baseline to Year 1
timeFrame: Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 1
measure: Time to First Study Drug Discontinuation During 2 Years
timeFrame: Week 0 to year 2
measure: Time to First Treatment Intensification (Add-on) or Change (Switch) After Randomization During 2 Years
timeFrame: Week 0 to year 2
measure: Percentage of Medication Possession Ratio (MPR) for Study Drug Medication Adherence for the First Year of the Study
timeFrame: Week 0 to year 1
measure: Number of Hypoglycemic Episodes Leading to an Inpatient Admission or Emergency Room (ER) Encounter From Baseline to Year 2
timeFrame: Baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2
measure: Diabetes Treatment Satisfaction Questionnaire, Change Version (DTSQc), Total Treatment Satisfaction Score Measured at Year 1
timeFrame: At year 1
measure: DTSQc, Total Treatment Satisfaction Score Measured at Year 2
timeFrame: At year 2
measure: Change From Baseline in Short Form 12-Item Version 2 Survey (SF-12 v2), Physical Component Summary (PCS-12) Score at Year 1
timeFrame: Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 1
measure: Change From Baseline in SF-12 v2, PCS-12 Score at Year 2
timeFrame: Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 2
measure: Change From Baseline in SF-12 v2, Mental Component Summary (MCS-12) Score at Year 1
timeFrame: Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 1
measure: Change From Baseline in SF-12 v2, MCS-12 Score at Year 2
timeFrame: Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 2
measure: Change From Baseline in Work Productivity and Activity Impairment, General Health Questionnaire (WPAI-GH) Absenteeism (Work Time Missed) Score at Year 1
timeFrame: Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 1
measure: Change From Baseline in WPAI-GH Absenteeism (Work Time Missed) Score at Year 2
timeFrame: Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 2
measure: Change From Baseline in WPAI-GH Presenteeism (Impairment at Work/Reduced On-the-job Effectiveness) Score at Year 1
timeFrame: Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 1
measure: Change From Baseline in WPAI-GH Presenteeism (Impairment at Work/Reduced On-the-job Effectiveness) Score at Year 2
timeFrame: Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 2
measure: Change From Baseline in WPAI-GH Work Productivity Loss (Overall Work Impairment/Absenteeism Plus Presenteeism) Score at Year 1
timeFrame: Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 1
measure: Change From Baseline in WPAI-GH Work Productivity Loss (Overall Work Impairment/Absenteeism Plus Presenteeism) Score at Year 2
timeFrame: Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 2
measure: Change From Baseline in WPAI-GH Activity Impairment Score at Year 1
timeFrame: Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 1
measure: Change From Baseline in WPAI-GH Activity Impairment Score at Year 2
timeFrame: Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 2
measure: All Cause Healthcare Resource Utilization (HCRU): Mean Number of Inpatient Admissions Per Participant From Baseline to Year 2
timeFrame: From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2
measure: All Cause HCRU: Mean Cumulative Length of Stay for Inpatient Admissions Per Participant From Baseline to Year 2
timeFrame: From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2
measure: All Cause HCRU: Mean Number of Emergency Room (ER) Encounters Per Participant From Baseline to Year 2
timeFrame: From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2
measure: All Cause HCRU: Mean Number of Outpatient Encounters Per Participant From Baseline to Year 2
timeFrame: From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2
measure: All Cause HCRU: Mean Number of Medication Visits Per Participant From Baseline to Year 2
timeFrame: From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2
measure: All Cause HCRU: Number of Participants With Inpatient Admission (Yes/No) From Baseline to Year 2
timeFrame: From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2
measure: All Cause HCRU: Number of Participants With ER Encounter (Yes/No) From Baseline to Year 2
timeFrame: From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2
measure: All Cause HCRU: Number of Participants With Outpatient Encounter (Yes/No) From Baseline to Year 2
timeFrame: From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2
measure: Diabetes Related HCRU: Mean Number of Diabetes Related Inpatient Admissions Per Participant From Baseline to Year 2
timeFrame: From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2
measure: Diabetes Related HCRU: Mean Cumulative Length of Stay for Diabetes Related Inpatient Admissions Per Participant From Baseline to Year 2
timeFrame: From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2
measure: Diabetes Related HCRU: Mean Number of Diabetes Related ER Encounters Per Participant From Baseline to Year 2
timeFrame: From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2
measure: Diabetes Related HCRU: Mean Number of Diabetes Related Outpatient Encounters Per Participant From Baseline to Year 2
timeFrame: From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2
measure: Diabetes Related HCRU: Mean Number of Diabetes Related Medication Visits Per Participant From Baseline to Year 2
timeFrame: From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2
measure: Diabetes Related HCRU: Number of Participants With Diabetes Related Inpatient Admission (Yes/No) From Baseline to Year 2
timeFrame: From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2
measure: Diabetes Related HCRU: Number of Participants With Diabetes Related ER Encounter (Yes/No) From Baseline to Year 2
timeFrame: From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2
measure: Diabetes Related HCRU: Number of Participants With Diabetes Related Outpatient Encounter (Yes/No) From Baseline to Year 2
timeFrame: From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2
measure: Number of Participants Who Attained Individualized HbA1c Target at Year 2 (Yes/No)
timeFrame: At year 2
measure: Number of Participants With HbA1c Less Than 7.0% (53 mmol/Mol) or At Least 1% Point Improvement in HbA1c Compared to Baseline at Year 2 (Yes/No)
timeFrame: At year 2
measure: Number of Participants With HbA1c Less Than 8.0% (64 mmol/Mol) at Year 1 (Yes/No)
timeFrame: At year 1
measure: Number of Participants With HbA1c Less Than 8.0% (64 mmol/Mol) at Year 2 (Yes/No)
timeFrame: At year 2
measure: Number of Participants With HbA1c Less Than 7.0% (53 mmol/Mol) and No Further Antidiabetic Medication Intensification After Randomization at Year 1 (Yes/No)
timeFrame: At year 1
measure: Number of Participants With HbA1c Less Than 7.0% (53 mmol/Mol) and No Further Antidiabetic Medication Intensification After Randomization at Year 2 (Yes/No)
timeFrame: At year 2
measure: Number of Participants With HbA1c Target Attainment Per Healthcare Effectiveness Data and Information Set (HEDIS) Criteria at Year 2 (Yes/No)
timeFrame: At year 2
measure: Number of Participants With HbA1c Less Than 7.0% (53 mmol/Mol) at Year 1 in Participants With HbA1c >9.0% at Baseline (Yes/No)
timeFrame: At year 1
measure: Number of Participants With HbA1c Less Than 7.0% (53 mmol/Mol) at Year 2 in Participants With HbA1c >9.0% at Baseline (Yes/No)
timeFrame: At year 2
measure: Number of Participants With HbA1c Less Than 8.0% (64 mmol/Mol) at Year 1 in Participants With HbA1c >9.0% at Baseline (Yes/No)
timeFrame: At year 1
measure: Number of Participants With HbA1c Less Than 8.0% (64 mmol/Mol) at Year 2 in Participants With HbA1c >9.0% at Baseline (Yes/No)
timeFrame: At year 2
measure: Percentage Change in Body Weight From Baseline to Year 2
timeFrame: Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 2
measure: Change in Body Weight (in Pounds) From Baseline to Year 2
timeFrame: Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 2
measure: Change in Systolic Blood Pressure (SBP) From Baseline to Year 2
timeFrame: Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 2
measure: Change in Diastolic Blood Pressure (DBP) From Baseline to Year 2
timeFrame: Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 2
measure: Number of Participants With Reported Hypoglycemia Leading to Inpatient Admission or ER Encounter During Year 1 (Yes/No)
timeFrame: Week 0 to year 1
measure: Number of Participants With Reported Hypoglycemia Leading to Inpatient Admission or ER Encounter During Year 2 (Yes/No)
timeFrame: Week 0 to year 2
measure: Number of Participants With HbA1c Less Than 7.0% (53 mmol/Mol) Without Experiencing Hypoglycemia Leading to Inpatient Admission or ER Encounter and Body Weight Loss of ≥ 5% Versus Baseline at Year 1 (Yes/No)
timeFrame: At year 1
measure: Number of Participants With Absolute HbA1c Reduction of ≥ 0.5% Without Experiencing Hypoglycemia Leading to Inpatient Admission or ER Encounter and a Body Weight Loss of ≥ 5% Versus Baseline at Year 1 (Yes/No)
timeFrame: At year 1
measure: Number of Participants With HbA1c Less Than 7.0% (53 mmol/Mol) Without Experiencing Hypoglycemia Leading to Inpatient Admission or ER Encounter and Body Weight Loss of ≥ 5% Versus Baseline at Year 2 (Yes/No)
timeFrame: At year 2
measure: Number of Participants With Absolute HbA1c Reduction of ≥ 0.5% Without Experiencing Hypoglycemia Leading to Inpatient Admission or ER Encounter and a Body Weight Loss of ≥ 5% Versus Baseline at Year 2 (Yes/No)
timeFrame: At year 2
measure: Number of Participants With HbA1c Less Than 7.0% (53 mmol/Mol) Without Experiencing Hypoglycemia Leading to Inpatient Admission or ER Encounter and No Body Weight Gain Versus Baseline at Year 1 (Yes/No)
timeFrame: At year 1
measure: Number of Participants With HbA1c Less Than 7.0% (53 mmol/Mol) Without Experiencing Hypoglycemia Leading to Inpatient Admission or ER Encounter and No Body Weight Gain Versus Baseline at Year 2 (Yes/No)
timeFrame: At year 2
measure: Percentage of Medication Possession Ratio (MPR) for Study Drug Medication Adherence For The Two Years of The Study
timeFrame: Week 0 to year 2
Other outcomes:
Locations:
city: Buena Park
country: United States
facility: American Clinical Trials
state: California
city: Fullerton
country: United States
facility: St. Jos Heritage Hlthcr_Fllrtn
state: California
city: Garden Grove
country: United States
facility: SC Clinical Research, Inc.
state: California
city: Lancaster
country: United States
facility: New Hope Consulting & Clinical Trials
state: California
city: Lancaster
country: United States
facility: OM Research LLC
state: California
city: Los Alamitos
country: United States
facility: Pacific Clinical Studies
state: California
city: Milpitas
country: United States
facility: Pacific Medical Center
state: California
city: Mission Hills
country: United States
facility: Facey Medical Foundation
state: California
city: Monterey
country: United States
facility: Monterey Endocrine & Diabetes Institute, Inc
state: California
city: Napa
country: United States
facility: Do-Eun Lee
state: California
city: Oxnard
country: United States
facility: Format Medical Research
state: California
city: San Jose
country: United States
facility: Joselito C Cabaccan, MD
state: California
city: Toluca Lake
country: United States
facility: Premier Medical Center, Inc.
state: California
city: Torrance
country: United States
facility: Adnab Research/Prestige Care Physician
state: California
city: Tulare
country: United States
facility: Altura Centers For Health
state: California
city: Visalia
country: United States
facility: Tariq Javed, MD Inc.
state: California
city: Walnut Creek
country: United States
facility: Endocrinology & Diabetes Specialists
state: California
city: Denver
country: United States
facility: University of Colorado Hospital
state: Colorado
city: Englewood
country: United States
facility: Denver Endocrinology Diabetes and Thyroid Center
state: Colorado
city: Bristol
country: United States
facility: ProHealth Physicians/OptumCare
state: Connecticut
city: Danbury
country: United States
facility: Western Connecticut Health Network_Danbury
state: Connecticut
city: Hamden
country: United States
facility: Endocrine Associates of Connecticut
state: Connecticut
city: Milford
country: United States
facility: Ismail Tarkhan MD
state: Connecticut
city: Milford
country: United States
facility: Steven L. Saunders MD LLC
state: Connecticut
city: Atlanta
country: United States
facility: The Kaufmann Clinic, Inc.
state: Georgia
city: Atlanta
country: United States
facility: Primary Care Research
state: Georgia
city: Augusta
country: United States
facility: Southern Family Medical Center
state: Georgia
city: Blue Ridge
country: United States
facility: River Birch Research Alliance, LLC
state: Georgia
city: Buford
country: United States
facility: Gwinnett Research Insti/Buford Family Pract Urgent Care Ctr
state: Georgia
city: Columbus
country: United States
facility: Centricity Research
state: Georgia
city: LaGrange
country: United States
facility: Medical Care of LaGrange
state: Georgia
city: Lilburn
country: United States
facility: Beaver Ruin Primary Care
state: Georgia
city: Locust Grove
country: United States
facility: Privia Medical Group of Georgia LLC
state: Georgia
city: Marietta
country: United States
facility: DC Research Works
state: Georgia
city: Marietta
country: United States
facility: Urban Family Practice Assoc
state: Georgia
city: Roswell
country: United States
facility: Atlanta Center for Clinical Research
state: Georgia
city: Sandersville
country: United States
facility: Sandersville Family Practice
state: Georgia
city: Savannah
country: United States
facility: Meridian Clin Res, LLC
state: Georgia
city: Statesboro
country: United States
facility: Family Health Care Center
state: Georgia
city: Stockbridge
country: United States
facility: Eagles Landing Diabetes/Endocrinology
state: Georgia
city: Suwanee
country: United States
facility: Herman Clinical Research LLC
state: Georgia
city: Suwanee
country: United States
facility: Sugarloaf Medical, PC
state: Georgia
city: Swainsboro
country: United States
facility: East Georgia Healthcare Center Inc
state: Georgia
city: Waycross
country: United States
facility: Coastal Care Medical Clinic
state: Georgia
city: Anderson
country: United States
facility: St. Vincent Research Institute
state: Indiana
city: Avon
country: United States
facility: American Health Network of Indiana, LLC_Avon_0
state: Indiana
city: Berne
country: United States
facility: Adams County Family Physicians
state: Indiana
city: Evansville
country: United States
facility: Deaconess Clinic, Inc.
state: Indiana
city: Fort Wayne
country: United States
facility: Associated Surgeons & Physicians LLC
state: Indiana
city: Franklin
country: United States
facility: American Health Network of IN LLC_Franklin
state: Indiana
city: Greenfield
country: United States
facility: American Health Network of Indiana, LLC_Greenfield
state: Indiana
city: Michigan City
country: United States
facility: La Porte County Institute For Clinical Research
state: Indiana
city: Mishawaka
country: United States
facility: Beacon Medical Group Swartz-Weikamp
state: Indiana
city: Muncie
country: United States
facility: American Health Network of IN LLC
state: Indiana
city: New Albany
country: United States
facility: American Health Network of Indiana, LLC
state: Indiana
city: Richmond
country: United States
facility: Reid Endocrinology Center
state: Indiana
city: Ashland
country: United States
facility: Regional Endorine and Diabetes Associates
state: Kentucky
city: Ashland
country: United States
facility: Tri State Primary Caregrayson Health Park
state: Kentucky
city: Covington
country: United States
facility: St Elizabeth Physicians Heart
state: Kentucky
city: Owensboro
country: United States
facility: The Endocrine & Diabetes Center
state: Kentucky
city: Paris
country: United States
facility: Paris Family Physicians PLLC
state: Kentucky
city: Richmond
country: United States
facility: Gaurang B. Shah, MD
state: Kentucky
city: Belfast
country: United States
facility: WCMP Family Medicine
state: Maine
city: Sterling Heights
country: United States
facility: Tri-County Research, Inc.
state: Michigan
city: Chesterfield
country: United States
facility: Diabetes & Endo Specialists Inc
state: Missouri
city: Columbia
country: United States
facility: University Of Missouri - Columbia
state: Missouri
city: Jefferson City
country: United States
facility: Jefferson City Medical Group, PC
state: Missouri
city: Saint Louis
country: United States
facility: Saint Louis University
state: Missouri
city: Saint Louis
country: United States
facility: South County Endocrinology and Obesity Medicine, LLC
state: Missouri
city: Springfield
country: United States
facility: Trinity Healthcare
state: Missouri
city: Las Vegas
country: United States
facility: Palm Research Center Inc-Vegas
state: Nevada
city: Albany
country: United States
facility: Albany Medical College - Endo
state: New York
city: Brooklyn
country: United States
facility: Prominis Medical Services PC
state: New York
city: Great Neck
country: United States
facility: Northwell Health Div of Endo
state: New York
city: Great Neck
country: United States
facility: Advanced Internal Medicine Group
state: New York
city: New York
country: United States
facility: NYC Research, Inc.
state: New York
city: New York
country: United States
facility: NYU Grossman School of Med
state: New York
city: Yonkers
country: United States
facility: EDOC LLP
state: New York
city: Charlotte
country: United States
facility: OnSite Clinical Solutions, LLC_Charlotte_0
state: North Carolina
city: Charlotte
country: United States
facility: OnSite Clinical Solutions, LLC_Charlotte
state: North Carolina
city: Fargo
country: United States
facility: Valley Weight Loss Clinic
state: North Dakota
city: Blanchester
country: United States
facility: Catherine LaRuffa, M.D., Inc.
state: Ohio
city: Canton
country: United States
facility: Diab & Endo Assoc of Stark Co
state: Ohio
city: Carlisle
country: United States
facility: Medical Frontiers, LLC
state: Ohio
city: Cleveland
country: United States
facility: University Hospitals of Cleveland Case Medical Center
state: Ohio
city: Columbus
country: United States
facility: Central Ohio Clinical Research LLC
state: Ohio
city: Columbus
country: United States
facility: Centricity Research
state: Ohio
city: Franklin
country: United States
facility: Franklin Family Practice
state: Ohio
city: Franklin
country: United States
facility: Prestige Clinical Research
state: Ohio
city: Mason
country: United States
facility: Functional Endocrinology
state: Ohio
city: Wadsworth
country: United States
facility: New Venture Medical Research
state: Ohio
city: Harleysville
country: United States
facility: Harleysville Medical Associates
state: Pennsylvania
city: McMurray
country: United States
facility: Primary Care Research South, Inc
state: Pennsylvania
city: Pittsburgh
country: United States
facility: Preferred Primary Care Physicians_Pittsburgh
state: Pennsylvania
city: Athens
country: United States
facility: Athens Medical Group
state: Tennessee
city: Bristol
country: United States
facility: PMG Research of Bristol
state: Tennessee
city: Humboldt
country: United States
facility: Murphy Research Center
state: Tennessee
city: McMinnville
country: United States
facility: Ascend Research Centers, Inc.
state: Tennessee
city: New Braunfels
country: United States
facility: Christus Trinity Clinic Hill Country Landa
state: Texas
city: Sugar Land
country: United States
facility: Simcare Medical Research, LLC
state: Texas
city: Saint George
country: United States
facility: Chrysalis Clinical Research
state: Utah
city: Arlington
country: United States
facility: The Endocrinology Group
state: Virginia
city: Chatham
country: United States
facility: Chatham Family Medical Center
state: Virginia
city: Colonial Heights
country: United States
facility: Swift Creek Family Care
state: Virginia
city: Daleville
country: United States
facility: Lawson Family Medicine & Aesthetics
state: Virginia
city: Danville
country: United States
facility: Privia Medical Group LLC
state: Virginia
city: Falls Church
country: United States
facility: Seven Corners Medical
state: Virginia
city: Hampton
country: United States
facility: Hampton Family Practice
state: Virginia
city: Lynchburg
country: United States
facility: Medical Associates of Central Virginia, Inc.
state: Virginia
city: Newport News
country: United States
facility: C. Lee Ginsburgh
state: Virginia
city: Portsmouth
country: United States
facility: Family Medicine Healthcare
state: Virginia
city: Radford
country: United States
facility: Family Health Clinic
state: Virginia
city: South Boston
country: United States
facility: Halifax Internal Medicine
state: Virginia
city: Suffolk
country: United States
facility: Hampton Roads Center for Clinical Research
state: Virginia
city: Virginia Beach
country: United States
facility: Endocrinology Consultants
state: Virginia
city: Virginia Beach
country: United States
facility: Corporation Lane Research Center
state: Virginia
city: Warrenton
country: United States
facility: Piedmont Family Practice PLC
state: Virginia
city: Williamsburg
country: United States
facility: Family Care of Williamsburg
state: Virginia
city: Green Bay
country: United States
facility: St. Vincent Hosp-Prevea Health
state: Wisconsin
city: Milwaukee
country: United States
facility: Ascension Medical Group- Germantown Clinic
state: Wisconsin
city: Milwaukee
country: United States
facility: Medical College of Wisconsin & Zablocki VAMC
state: Wisconsin
city: London
country: Canada
facility: Western University Medical Center at WU of Health Sciences
state: Ontario
Study officials:
affiliation: Novo Nordisk A/S
name: Clinical Reporting Anchor and Disclosure (1452)
role: STUDY_DIRECTOR
References: